Medical diagnostics transformed healthcare delivery in 2025.
Point-of-care testing expanded beyond COVID. At-home diagnostics became standard. AI enhanced accuracy across all testing modalities. Decentralized labs challenged traditional models.
Investment follows innovation. VCs back molecular diagnostics, digital pathology, and rapid testing platforms. Strategic buyers acquire proven technologies. Early-stage funding flows to novel biomarkers.
This guide lists 35+ active diagnostics investors in 2025. Their specific focus areas. Investment criteria. Direct contacts.
Track your diagnostics pitch deck
Clinical validation complete. CLIA certification secured. Pilot labs converting.
Yet investors don't respond.
Stop sending static PDFs. Track real engagement. See which data slides get attention.
Ellty shows exactly how investors review your deck.
Top 35 diagnostics investors
1. Labcorp Venture Fund
Strategic investor from diagnostics giant backing innovation in testing.
Investment focus: Diagnostic innovations, biomarkers, platforms, point-of-care solutions
Investment range: Early stage, strategic investments
Notable investments: 70+ direct investments, $265M+ deployed since 2012
Contact: labcorp.com/venture-fund
2. Illumina Ventures
Genomics leader's venture arm focused on sequencing applications.
Investment focus: Liquid biopsy, molecular diagnostics, genomic testing
Investment range: Seed to Series B, $1M-$10M typical
Notable investments: Grail (spun out), diagnostics platforms
Contact: illuminaventures.com
3. Forbion Capital Partners
European life sciences investor with diagnostics expertise.
Investment focus: Molecular diagnostics, companion diagnostics, liquid biopsy
Investment range: Series A-C, €5M-€25M
Notable investments: Biocartis, MDxHealth, diagnostics exits
Contact: forbion.com
4. NGN Capital
Global healthcare investor focused on diagnostics transformation.
Investment focus: Next-gen diagnostics, molecular testing, digital pathology
Investment range: Series B+, $10M-$50M
Notable investments: Multiple diagnostics companies
Contact: ngncapital.com
5. OrbiMed
Leading healthcare investor with dedicated diagnostics team.
Investment focus: Molecular diagnostics, liquid biopsy, precision diagnostics
Investment range: All stages, $5M-$100M+
Notable investments: Foundation Medicine (exit), Guardant Health
Contact: orbimed.com
6. Menlo Ventures
Silicon Valley firm with healthcare diagnostics practice.
Investment focus: Digital diagnostics, AI-powered testing, lab automation
Investment range: Series A-C, $10M-$50M
Notable investments: Cofactor Genomics, diagnostics platforms
Contact: menloventures.com
7. ARCH Venture Partners
Pioneer in commercializing diagnostic innovations.
Investment focus: Breakthrough diagnostics, liquid biopsy, early detection
Investment range: Seed to growth, patient capital
Notable investments: Grail co-founder, multiple diagnostics
Contact: archventure.com
8. Foresite Capital
Healthcare-focused firm with diagnostics expertise.
Investment focus: Precision diagnostics, molecular testing, AI diagnostics
Investment range: Series A-D, $10M-$100M
Notable investments: 10x Genomics, diagnostics platforms
Contact: foresitecapital.com
9. T. Rowe Price
Growth investor active in diagnostics scale-ups.
Investment focus: Commercial-stage diagnostics, liquid biopsy leaders
Investment range: Late stage, $20M-$200M+
Notable investments: Public and private diagnostics companies
Contact: troweprice.com
10. Third Rock Ventures
Company builder focused on transformative diagnostics.
Investment focus: Novel diagnostic platforms, early cancer detection
Investment range: Company formation to Series B
Notable investments: Thrive Earlier Detection ($110M launch)
Contact: thirdrockventures.com
11. Samsara BioCapital
Life sciences investor with diagnostics portfolio.
Investment focus: Precision diagnostics, biomarker discovery
Investment range: Series A-C, $5M-$30M
Notable investments: Diagnostics and therapeutics convergence
Contact: samsarabio.com
12. DCVC (Data Collective)
Deep tech investor backing computational diagnostics.
Investment focus: AI diagnostics, computational pathology
Investment range: Seed to Series B, $3M-$20M
Notable investments: Cofactor Genomics, data-driven diagnostics
Contact: dcvc.com
13. Northpond Ventures
Global science investor focused on diagnostics innovation.
Investment focus: Multi-omics diagnostics, precision testing
Investment range: Series A-D, $10M-$50M
Notable investments: Advanced diagnostics platforms
Contact: northpondventures.com
14. Rock Springs Capital
Healthcare growth investor with diagnostics focus.
Investment focus: Commercial-stage diagnostics, specialty testing
Investment range: Series B+, $15M-$75M
Notable investments: Diagnostics services companies
Contact: rockspringscapital.com
15. Arboretum Ventures
Midwest healthcare VC with diagnostics expertise.
Investment focus: Medical diagnostics devices, molecular diagnostics
Investment range: Series A-B, $3M-$15M
Notable investments: NeuMoDx (exit to QIAGEN)
Contact: arboretumvc.com
16. Cowen Healthcare Investments
Healthcare specialist with diagnostics practice.
Investment focus: Molecular diagnostics, liquid biopsy, lab services
Investment range: Series A-C, $5M-$40M
Notable investments: Multiple diagnostics platforms
Contact: cowen.com
17. New Enterprise Associates (NEA)
Large fund with dedicated diagnostics team.
Investment focus: Breakthrough diagnostics, platform technologies
Investment range: Seed to growth, $5M-$100M+
Notable investments: Multiple diagnostics unicorns
Contact: nea.com
18. Venrock
Pioneer healthcare investor with diagnostics legacy.
Investment focus: Novel diagnostic approaches, precision medicine
Investment range: Early to growth stage
Notable investments: Historic diagnostics leaders
Contact: venrock.com
19. DFJ Growth
Growth investor backing diagnostics scale-ups.
Investment focus: Late-stage diagnostics, market leaders
Investment range: Series C+, $25M-$200M
Notable investments: Delfi Diagnostics Series B lead
Contact: dfj.com
20. Windham Venture Partners
Healthcare venture firm with diagnostics focus.
Investment focus: Early detection, molecular diagnostics
Investment range: Seed to Series B, $2M-$15M
Notable investments: Multiple early-stage diagnostics
Contact: windhamvp.com
21. AV8 Ventures
Silicon Valley firm investing in diagnostics innovation.
Investment focus: AI diagnostics, digital health diagnostics
Investment range: Seed to Series A, $1M-$10M
Notable investments: Next-gen diagnostics platforms
Contact: av8.vc
22. Osage University Partners
University-affiliated investor in diagnostics.
Investment focus: Academic spinouts, novel diagnostics
Investment range: Seed to Series B, $1M-$15M
Notable investments: University diagnostics technologies
Contact: osageup.com
23. Point72 Ventures
Steve Cohen's venture arm active in diagnostics.
Investment focus: Data-driven diagnostics, AI applications
Investment range: Series A-C, $5M-$50M
Notable investments: Delfi Diagnostics, others
Contact: point72ventures.com
24. Y Combinator
Leading accelerator funding diagnostics startups.
Investment focus: Early-stage diagnostics across all categories
Investment range: $500K for 7%
Notable investments: BillionToOne, Cofactor, Orange Health
Contact: ycombinator.com
25. Artiman Partners
Silicon Valley firm with diagnostics expertise.
Investment focus: Novel diagnostic technologies, platforms
Investment range: Series A-B, $5M-$20M
Notable investments: Multiple diagnostics companies
Contact: artiman.com
26. Digitalis Ventures
Life sciences specialist focused on diagnostics.
Investment focus: Next-gen diagnostics, precision medicine
Investment range: Seed to Series A, $1M-$10M
Notable investments: Early-stage diagnostics platforms
Contact: digitalisventures.com
27. IndieBio
Biotech accelerator with diagnostics track.
Investment focus: Novel diagnostic approaches, bio-based testing
Investment range: $250K initial investment
Notable investments: Diagnostics startups globally
Contact: indiebio.co
28. Breakout Ventures
Hard science investor backing diagnostics innovation.
Investment focus: Novel diagnostic technologies, deep tech
Investment range: Seed to Series A, $1M-$5M
Notable investments: Scientific breakthrough diagnostics
Contact: breakoutventures.com
29. Medtronic Ventures
Strategic investor from medical device leader.
Investment focus: Point-of-care diagnostics, connected devices
Investment range: Strategic investments, varies
Notable investments: Diagnostics device companies
Contact: medtronicventures.com
30. Brown Advisory
Growth investor active in diagnostics.
Investment focus: Commercial-stage diagnostics companies
Investment range: Late stage, $20M+
Notable investments: Delfi participant, others
Contact: brownadvisory.com
31. QIAGEN Ventures
Strategic investor from diagnostics tools leader.
Investment focus: Molecular diagnostics, sample technologies
Investment range: Strategic investments
Notable investments: Complementary diagnostics technologies
Contact: qiagen.com
32. Advantage Capital
Impact investor backing diagnostics in underserved markets.
Investment focus: Diagnostics accessibility, lab services
Investment range: $3M-$10M typical
Notable investments: Gravity Diagnostics ($5M)
Contact: advantagecap.com
33. High-Tech Gründerfonds
German seed investor active in diagnostics.
Investment focus: European diagnostics startups
Investment range: Seed, €600K-€3M
Notable investments: Multiple German diagnostics companies
Contact: htgf.de
34. Paua Ventures
Berlin-based investor with healthtech focus.
Investment focus: Digital diagnostics, AI-powered testing
Investment range: Pre-seed to Series C
Notable investments: European diagnostics platforms
Contact: pauaventures.com
35. EIC (European Innovation Council)
EU fund supporting diagnostics innovation.
Investment focus: Breakthrough European diagnostics
Investment range: Grants and equity, up to €15M
Notable investments: Deep tech diagnostics
Contact: eic.ec.europa.eu
Pitching diagnostics investors
Key metrics that matter
Clinical performance: Sensitivity >90%, specificity >95%
Regulatory status: FDA pathway defined, CLIA certified
Unit economics: Path to <$100 COGS
Reimbursement: CPT code strategy, payer interest
What gets meetings
Strong clinical data beats everything. One-page clinical summary. Key physician champions named.
Health economics analysis essential. Show cost savings per patient. Demonstrate improved outcomes.
Common mistakes
Comparing to Theranos. Don't.
No reimbursement strategy. Fatal.
Tech-first pitch. Lead with clinical need.
Alternative funding sources
Strategic investors
Quest Diagnostics Ventures: Partners for distribution
LabCorp Venture Fund: $265M+ deployed
Roche Venture Fund: Companion diagnostics focus
Abbott Ventures: Point-of-care expertise
Government grants
NIH SBIR/STTR: Up to $3M for diagnostics
BARDA: Pandemic preparedness diagnostics
EU Horizon Europe: €2.5M for breakthrough diagnostics
NSF: Technology platform grants
Accelerators
Y Combinator: $500K for 7% equity
IndieBio: $250K plus lab space
MedTech Innovator: Non-dilutive accelerator
Johnson & Johnson Innovation: JLABS access
Success stories
Liquid biopsy leaders
Grail: Spun from Illumina. Raised $2B+. UK deployment deal.
Delfi Diagnostics: $225M Series B in 2022. Fragmentomics approach.
Thrive Earlier Detection: $110M Series A. Johns Hopkins technology.
Point-of-care winners
LumiraDx: $300M+ raised. COVID to broader menu.
Cue Health: IPO during pandemic. Home testing platform.
Detect: $38M Series B. Home molecular testing.
Why diagnostics startups fail
Technology seeking application. No clear use case. Nice-to-have not must-have.
Reimbursement assumptions wrong. Payers won't cover. Price point too high.
Slow clinical adoption. Physicians resist change. No champion users.
How Ellty helps diagnostics startups
Diagnostics pitch decks need different focus. Clinical data matters most. Regulatory slides get scrutinized.
Ellty data shows:
- Clinical validation slides: 4x longer view time
- Reimbursement strategy: Most forwarded section
- Team clinical experience: Second most viewed
Track what resonates. Know which investors understand diagnostics.
Diagnostics founders using Ellty see:
- 3x response rate vs. PDFs
- Identify investors who "get" diagnostics
- Know when forwarded to clinical advisors
FAQs
Q: How much to raise for diagnostics startup?
$5-10M Series A typical. Higher than therapeutics due to lab buildout.
Q: LDT or FDA approval first?
LDT for initial revenue. FDA for scale. Investors want both paths.
Q: When to approach strategics?
After clinical validation. They want de-risked assets.
Q: Single cancer or pan-cancer?
Start focused. Expand after proving first indication.
Q: How important is CLIA certification?
Critical for US market. Get it before Series A.
